Reveal What Couldn’t Be Seen Before for Unprecedented Confidence and Insight Into Disease
The Singulex Clarity® system* can help clinicians deliver the right treatment at the right time.
- More sensitive than other immunoassay technologies to inform patient care and speed clinical decision-making
- Empowers clinicians to distinguish healthy patients from those who are not
* Singulex Clarity system is in development and is not available for commercial sale in the United States.
The Singulex Clarity System* is a fully automated in vitro diagnostics platform that is designed to deliver groundbreaking advancements in immunoassay technology through ultra-sensitive Single Molecule Counting technology. The system provides precise results across a 6-log reporting range. Full automation, ready-to-use reagents, and on-board resource inventory management provide a streamlined sample-in, result-out workflow to optimize laboratory operations.
Features
- Ready-to-use assay reagents do not require special handling prior to use
- Bar coding for sample and reagent tracking
- Simple and intuitive operation
- Integrated Single Molecule Counting technology reading system
- Advanced workflow
- Built-in touch screen with simple graphical user interface
- Onboard capacity for 12 assays
- Walkaway time: 90 minutes
- Capacity to hold 48 primary sample tubes
- LIS connectivity
- Throughput: 144-240 results per 8-hour shift.** Includes set-up, control run, and daily maintenance.
- Capacitive liquid level detection
- Clot detection
- Continuous inventory of on-board resources
- Automated, one-step immunoassays
- Capable of adapting to additional sample types or assay protocols
* Singulex Clarity system is in development and is not available for commercial sale in the United States.
**Values based on running 1 test per sample up to 5 tests per sample.
Singulex’s Single Molecule Counting technology is up to 1000 times more sensitive than contemporary immunoassay platforms, measuring biomarkers at ultra-low levels other tests cannot.
Singulex’s Single Molecule Counting technology can be applied to existing and newly identified biomarkers to aid physician decision making in cardiovascular, oncology, infectious disease, inflammation/immunology, and CNS applications.
How Single Molecule Counting Technology Works
Singulex technology couples proprietary digital Single Molecule Counting technology with robust microparticle-based immunoassays to provide higher sensitivity and broader dynamic range than contemporary immunoassay systems.3 A biological sample (e.g. blood plasma) containing the analyte of interest is combined with paramagnetic microparticles coated with capture antibodies and detection antibodies labeled with fluorescent dye. After a brief incubation, the microparticles are washed to remove any excess detection antibody and then subjected to conditions that disrupt the sandwich complex formed on the microparticles. The resulting eluate, which contains the fluorescently-labeled detection antibodies, is separated from the microparticles and analyzed using Single Molecule Counting technology. Single fluorescently-labeled molecules that pass through a small interrogation space created by a confocal detection system (see below) generate intense flashes of light as they are illuminated by a laser.
The confocal microscopic optics utilized in Single Molecule Counting technology rotate and scan through the bottom of a detection vessel. The intensity of fluorescence encountered in the interrogation space (orange dot) is captured as a function of time. The measured fluorescence is sequestered in 100 micro second time bins as shown below.
A threshold of signal intensity (dotted line) is applied across all time bins and only bins with fluorescence above the threshold are counted as detected digital events. Each of these counted digital events represents a single fluorescently-labeled molecule. The sum of digital events is equivalent to the concentration of analyte in the original biological sample. The Single Molecule Counting technology provides a reading range of more than 6 logs.
Proprietary Intellectual Property
Singulex’s pioneering research has yielded a broad and deep global intellectual property portfolio that includes both Single Molecule Counting technology as well as numerous biomarkers for cardiovascular, oncology, infectious disease, and inflammation/immunology applications.